

Adherence and Persistence Among Chronic Myeloid Leukemia Patients During Second-Line Tyrosine Kinase Inhibitor Treatment

TABLE 3 Measures of Adherence (IPTW)

	Dasatinib N= 219		Nilotinib N= 158		P Value
Medication possession ratio					
Mean, SD	0.88	0.21	0.84	0.28	0.036
Low adherence: <85% (n, %)	60	27.3	58	36.7	0.006
High adherence: ≥85% (n, %)	159	72.7	100	63.3	
Measurement of persistence					
Proportion of days covered, mean, SD	0.79	0.26	0.77	0.32	0.328
Estimated level of persistence					
Subsequent script within 1.5x days' supply (n, %)					
Treatment interruption	65	29.6	59	37.3	0.026
Persistent	154	70.4	99	62.7	
Subsequent script within 2x days' supply (n, %)					
Treatment interruption	36	16.3	35	22.4	0.033
Persistent	183	83.7	123	77.6	
Discontinuation: ≥ 2 fills (n, %)					
Treatment gap of 60 days	69	31.4	55	35.1	0.282
Treatment gap of 90 days	10	4.4	14	8.6	0.021
Days to discontinuation, mean, SD	165.1	79.5	153.2	77.6	0.623

IPTW = inverse probability treatment weighting; *SD* = standard deviation

LMC II[^] linea – first year

Baseline Characteristics	Dasatinib	Nilotinib
Number of patients	21	22
Mean years in age (SD)	58 (16)	53 (16)
Male gender, %	57,14	50
Sokal Risk (% patients)		
I	33,33	36,36
II	42,86	40,91
III	23,81	22,73
Adherence		
Mean (SD)	0,91 (0,12)	0,90(0,12)
Higher than 0,99, %	47,62	22,73

LMC II[^] linea – first year

Clinical outcomes (BCR/ABL)	Dasatinib	Nilotinib
% patients < 0,1%	95,24	95,46
adherence < 0,1%	0,92	0,89

Un nuovo cutoff?



PubMed



blood

2013 122: 872-884
doi:10.1182/blood-2013-05-501569 originally published
online June 26, 2013



Non smettere mai di seminare stelle, anche se a prima vista non si notano.

תודה
Dankie Gracias
Спасибо شكراً
Merci Takk
Köszönjük Terima kasih
Grazie Dziękujemy Děkojame
Ďakujeme Vielen Dank Paldies
Kiitos Tänname teid 谢谢
Thank You Tak
感謝您 Obrigado Teşekkür Ederiz
Σας Ευχαριστούμ 감사합니다
ඔබට ආචාර්ය
Bedankt Děkujeme vám
ありがとうございます
Tack